Bendamustine
Alkylating Agent
DB06769
Approved Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
0
Targets
0
Resistance Mutations
5
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Details
DrugBank ID
DB06769 ↗
Approval Date
2008-03-31
Molecular Weight
358.263 g/mol
Drug Class
Alkylating Agent
ATC Codes
L01AA09
Synonyms
Ribomustine
PubChem
CID: 65628 ↗
ChEMBL
CHEMBL487253 ↗
SMILES
CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
ADMET Profile
Computing properties…
Drug References (DrugBank)